Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: A questionnaire survey

Nephrology

Volumn 16, Issue 5, 2011, Pages 518-521

  Nakaya, Izaya ^a   Namikoshi, Tamehachi ^b   Tsuruta, Yuki ^c   Nakata, Takeshi ^d   Shibagaki, Yugo ^e   Onishi, Yoshihiro ^f   Fukuhara, Shunichi ^g  

^a Iwate Prefectural Central Hospital   (Japan)

^b Fukuyama City Hospital   (Japan)

^c TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^d OITA UNIVERSITY HOSPITAL   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL   (Japan)

^f Institute for Health Outcomes and Process Evaluation Research   (Japan)

^g KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

allopurinol; benzbromarone; cardiovascular disease; gout; urolithiasis

Indexed keywords

ALLOPURINOL; BENZBROMARONE; URIC ACID;

ASYMPTOMATIC DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG MEGADOSE; GOUT; HUMAN; HYPERURICEMIA; JAPANESE; LOW DRUG DOSE; NEPHROLOGIST; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; URIC ACID BLOOD LEVEL; UROLITHIASIS;

EID: 79959907670     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01446.x     Document Type: Review

References (23)

1. Chonchol M, Shlipak MG, Katz R, et al,. Relationship of uric acid with progression of kidney disease. Am. J. Kidney Dis. 2007; 50: 239-47. (Pubitemid 47095076)
2. Alderman MH, Cohen H, Madhavan S, Kivlighn S,. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-50. (Pubitemid 29325733)
3. Fang J, Alderman MH,. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-10. (Pubitemid 30257539)
4. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P,. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-8.
5. Suliman ME, Johnson RJ, Garcia-Lopez E, et al,. J-shaped mortality relationship for uric acid in CKD. Am. J. Kidney Dis. 2006; 48: 761-71. (Pubitemid 44740052)
6. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S,. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am. J. Kidney Dis. 2004; 44: 642-50. (Pubitemid 39237608)
7. Madero M, Sarnak MJ, Wang X, et al,. Uric acid and long-term outcomes in CKD. Am. J. Kidney Dis. 2009; 53: 796-803.
8. Mikuls TR, MacLean CH, Olivieri J, et al,. Quality of care indicators for gout management. Arthritis Rheum. 2004; 50: 937-43. (Pubitemid 38326194)
9. Culleton BF, Larson MG, Kannel WB, Levy D,. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann. Intern. Med. 1999; 131: 7-13. (Pubitemid 29310011)
10. Sakata K, Hashimoto T, Ueshima H, Okayama A, Group NDR,. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. Eur. J. Epidemiol. 2001; 17: 461-8. (Pubitemid 34105990)
11. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F, Group MS,. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp. Gerontol. 2008; 43: 347-52.
12. Japanese Society of Gout and Nucleic Acid Metabolism (ed). Guideline for the Management of Hyperuricemia and Gout, 2nd edn. Osaka: Medical view, 2010.
13. Levey AS, Eckardt KU, Tsukamoto Y, et al,. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-100. (Pubitemid 41623371)
14. Imai E, Horio M, Iseki K, et al,. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin. Exp. Nephrol. 2007; 11: 156-63. (Pubitemid 47012510)
15. Matsuo S, Imai E, Horio M, et al,. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009; 53: 982-92.
16. Schlesinger N, Moore DF, Sun JD, Schumacher HR Jr,. A survey of current evaluation and treatment of gout. J. Rheumatol. 2006; 33: 2050-2. (Pubitemid 44571881)
17. Siu YP, Leung KT, Tong MK, Kwan TH,. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 2006; 47: 51-9. (Pubitemid 41828266)
18. Goicoechea M, de Vinuesa SG, Verdalles U, et al,. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 2010; 5: 1388-93.
19. Terkeltaub R,. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res. Ther. 2009; 11.
20. Becker MA, Schumacher HR Jr, Wortmann RL, et al,. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 2005; 353: 2450-61. (Pubitemid 41781828)
21. Schumacher HR Jr, Becker MA, Wortmann RL, et al,. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59: 1540-8.
22. Japanese Society of Nephrology (ed). Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease 2009. Tokyo: Tokyoigakusha, 2009.
23. Ando Y, Ito S, Uemura O, et al,. CKD Clinical Practice Guidebook. The essence of treatment for CKD patients. Clin. Exp. Nephrol. 2009; 13: 191-248.